Abbott Labs Sells Developed Markets Generics Unit

July 14 (Bloomberg) -- Marshall Sonenshine, chairman and managing partner at Sonenshine Partners, and Jonathan Golub, chief U.S. market strategist at RBC Capital Markets, examine Abbott Laboratories selling its developed markets generic drug unit to Mylan in a deal worth $5.3 Billion and what it means to the current M&A market. They speak on “Bloomberg Surveillance.”
Too Much Greek Risk to Get Back Into Europe Stocks: BGC
43:46 - BGC Partners Market Strategist Michael Ingram says there's too much risk to revisit overweights in European equities because of uncertainty surrounding Greece. He spoke on Bloomberg's "Countdown" with Caroline Hyde and Ryan Chilcote. (Source: Bloomberg)
  • U.K. Retail Earnings: Breaking Down the Numbers
  • Iran Deal Still Likely Despite Delay: Former Ambassador
  • U.K. Is Still Overspending: Toogood